Large Inflow of Money Detected in Shire plc

Shire plc (SHPG) : On Tuesday, The money flowed into the Shire plc (SHPG) stock with an uptick to downtick ratio was recorded at 1.31. Transactions worth $32.99 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $25.22 million. The total money flow into the stock was $7.77 million. The block trades reveal a bullish bias with an up-down ratio of 2.57. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $8.11 million of block transactions on upticks. The value of block trades on downticks was $3.16 million, indicating lower selling interest. The total money flow in block trades was $4.95 million. In terms of price action, Shire plc (SHPG) traded down $0.18 during the session at $190.22. Compared to the previous days closing, the stock was down only by -0.09%. For the week, the stock is -0.24%, over previous weeks closing.


Also, Goldman Sachs maintains their rating on the shares of Shire plc (NASDAQ:SHPG). The current rating of the shares is Buy. The rating by the firm was issued on June 28, 2016.

Shire plc has lost 4.62% in the last five trading days and dropped 1.95% in the last 4 weeks. Shire plc has dropped 0.53% during the last 3-month period . Year-to-Date the stock performance stands at -6.82%.

Shire plc (NASDAQ:SHPG): The stock opened at $190.60 on Tuesday but the bulls could not build on the opening and the stock topped out at $191.19 for the day. The stock traded down to $189.80 during the day, due to lack of any buying support eventually closed down at $190.22 with a loss of -0.09% for the day. The stock had closed at $190.40 on the previous day. The total traded volume was 561,676 shares.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.